VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LNTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LNTHLantheus Holdings, Inc.
$102.00$6.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
LNTH logo

Lantheus Holdings, Inc.

LNTH
NASDAQ · Specialty & Generic Drugs
$102.00
At close - Nov 18, 4:00 PM EST - USD
Market Cap$6.64B
P/E25.9x
52W High$111.86
Volume946.68K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Net-Cash Balance Sheet Masks Volatile Earnings Momentum

Lantheus shows a flat top line, with Q3 2026 revenue up only 1.5% year over year to $389.9M, while quarterly net margins have compressed from a 34.6% peak in Q3 2024 to 5.7% in Q3 2026, suggesting underlying profitability is less durable than recent cash generation implies.

GrowthStable
ProfitabilityModerate
ValuationAttractive
TechnicalsStrong
Explore valuation models
MARKET ACTION

LNTH price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

+14% Peers

P/E is 14% above peer median

03

Market leadership

RS 89 · Leader

High momentum (Outperforming 89% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 5
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue has been essentially flat, with Q3 2026 growth of 1.5% and gross margin easing from roughly 64% to 62.4%, while operating margin swung between 8.3% and 35.3% across the reported quarters.

Analyst Consensus+0.6% target
Buy(19 analysts)
10 Buy9 Hold0 Sell

The Bull Case

Upside Catalysts

NASDAQ listed company

Lantheus Holdings is a publicly traded company on NASDAQ, providing liquidity and visibility to investors.

Diverse subsidiary portfolio

The company owns subsidiaries like Lantheus Medical Imaging, Progenics Pharmaceuticals, and EXINI Diagnostics, diversifying its business operations.

Real-time stock data availability

LNTH stock offers real-time price tracking and detailed financial overviews, aiding informed investment decisions.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
LNTH+51.63%
S&P 500 (^GSPC)+6.88%
1-Year Return
LNTH+90.65%
S&P 500 (^GSPC)+10.62%
3-Year Return
LNTH+47.57%
S&P 500 (^GSPC)+58.96%
5-Year Return
LNTH+252.21%
S&P 500 (^GSPC)+57.90%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
25.9x
Forward P/EExpansion
19.0x
EV/EBITDA75th %ile
18.1x
FCF YieldCash Flow
5.9%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
25.9x
20.5x
75th· Fair
EV/EBITDA
18.1x
12.6x
75th· Fair
Price/FCF
16.9x
13.7x
80th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$52.06-49.0%
Base (Fair)$87.83-13.5%
Bull$125.59+23.1%
$52.06 Bear$87.83 Base$125.59 Bull
Current Market Price: $102.00
Trades at a 16.1% premium to Base DCF ($87.83)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$1.54B+0.5% YoY
Net income FY25
$234M-25.2% YoY
Free cash flow FY25
$354M-28.2% YoY
Operating margin FY25
20.2%-9.6 pts YoY
ROIC (FY25)21.7%
Avg ROIC 5Y21%
ROE (TTM)21.7%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate10/12 (83%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$1.68+36.6%
vs $1.23
$390M+9.6%
vs $356M
Q3 2026
Aug 6, 2026
$1.55+19.2%
vs $1.30
$388M+6.9%
vs $363M
Q2 2026
May 7, 2026
$1.46+16.8%
vs $1.25
$377M+6.4%
vs $354M
Q1 2026
Feb 26, 2026
$1.67+41.5%
vs $1.18
$407M+10.8%
vs $367M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·2d ago
Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer's Disease

BEDFORD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced results from two pivotal Phase 3 studies evaluating the diagnostic performance of the TAUKLARIFY™ (florquinitau F 18 injection) PET imaging, also referred to as MK-6240, which supported FDA use in adults with cognitive impairment being evaluated for Alzheimer's disease to identify patients with neurofibrillary tangle (NFT) pathology.

PRNewsWire·Nov 9, 2026
PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility

Expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies WALTHAM, Mass., Nov. 9, 2026 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals, today announced a definitive agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH).

GlobeNewsWire·Nov 5, 2026
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now in effect Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now in effect

GlobeNewsWire·Nov 5, 2026
Lantheus Reports Third Quarter 2026 Financial Results

Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025 FDA approves TAUKLARIFY™ (florquinitau F-18 injection); an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer's disease FDA grants final approval for BRAVNETSA™ (lutetium Lu 177 dotatate); the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Announced on August 3, 2026 that the Company has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of the Company in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion BEDFORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2026.

Filtered for Lantheus Holdings, Inc.More Headlines
04

Compare before deciding

Benchmark LNTH against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Lantheus Holdings, Inc. (LNTH)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LNTH logoLNTHLantheus Holdings, Inc.Current
$102.00$6.64B25.850.5%17.28%21.72%—
RMD logoRMDResMed Inc.
$242.61$35.19B21.849.85%27.79%25.14%0.99%
BWXT logoBWXTBWX Technologies, Inc.
$117.93$10.8B28.9418.3%10.41%28.48%0.85%
ROIV logoROIVRoivant Sciences Ltd.
$38.73$27.98B-81.30-71.57%-838.19%-6.96%—
GE logoGEGE Aerospace
$328.10$340.42B37.5318.48%17.31%50%0.41%
GEHC logoGEHCGE HealthCare Technologies Inc.
$83.66$37.79B21.534.84%8.54%15.87%0.17%

Compare LNTH vs Peers

Lantheus Holdings, Inc. (LNTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RMD

Most directly comparable listed peer for LNTH.

Scale Benchmark

vs GE

Larger-name benchmark to compare LNTH against a more recognizable public peer.

Peer Set

Compare Top 5

vs RMD, BWXT, ROIV, GE

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

LNTH SEC Filings & Documents

Lantheus Holdings, Inc. (LNTH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Oct 22, 2026·SEC

Material company update

Oct 14, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 5, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

May 7, 2026·SEC

Get notified when LNTH posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LNTH Frequently Asked Questions

Lantheus Holdings, Inc. (LNTH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Lantheus Holdings, Inc.'s revenue?

Lantheus Holdings, Inc. (LNTH) reported $1.56B in revenue over the trailing twelve months. Revenue was $1.54B in fiscal year 2025. That is 435% more than the $288.1M of fiscal year 2012.

How fast is Lantheus Holdings, Inc. growing?

Lantheus Holdings, Inc. (LNTH) grew revenue by 2.4% over the trailing twelve months, compared with the twelve months before.

Is LNTH profitable?

Yes. Lantheus Holdings, Inc. (LNTH) earned $269.9M in net income over the trailing twelve months (a 17.3% net margin).

Dividend & Returns
What is LNTH's return on equity?

Lantheus Holdings, Inc. (LNTH) had a return on equity (ROE) of 21.7% over the trailing twelve months. That is well above the market's typical 10-15%.

What is Lantheus Holdings, Inc.'s free cash flow?

Lantheus Holdings, Inc. (LNTH) generated $393.1M in free cash flow over the trailing twelve months.

What if you invested $1,000 in LNTH back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →